▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / CLCS

CLCS — Cell Source, Inc.

—
OTC · Health Care · Pharmaceuticals · CIK 1569340 ·
Last close
$0.82
Market Cap
$55.72M
52W High
$0.98
52W Low
$0.56
ADV30
1,836
Next earnings
—
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2024 0 — -676,811 -331,307 286,500 74,631 18,824,336
Sep 2024 0 — -831,625 -1,417,141 264,660 22,992 19,205,216

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,387,336
Investing CF
—
Financing CF
$1,371,418
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.04
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-46,180,030
Inventory
—
Receivables
$50,000
ST Investments
—
EBIT TTM
$-1,109,480
Pretax Income TTM
$-1,748,448
Interest Exp TTM
$638,968
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 0 -3,840,244 -4,512,642 286,500 18,824,336 — -2,684,162
Dec 2023 0 -4,182,746 -5,321,212 195,171 15,806,714 — -2,347,891
Dec 2022 0 -4,175,333 -5,167,748 409,845 13,043,740 — -3,138,686
Dec 2021 0 -4,018,572 -5,472,435 313,767 10,139,902 — -3,378,682

Peers — same industry

TickerNameMarket CapLastDaily %
MCRB Seres Therapeutics, Inc. $55.20M $5.70 —
XLO Xilio Therapeutics, Inc. $54.64M $8.31 —
IMMP IMMUTEP Ltd $53.05M $0.36 —
PDSB PDS Biotechnology Corp $58.61M $1.05 —
PMVP PMV Pharmaceuticals, Inc. $59.20M $1.11 —

News headlines (Yahoo Finance, 1h cache)

Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles Thi
2026-05-21 13:00 · Yahoo
Cell Source, Inc. to Present at the LD Micro Invitational XVI
2026-05-14 20:00 · Yahoo
Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent
2026-01-15 21:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →